Skip Nav Destination
Issues
1 August 2023
-
Cover Image
Cover Image
The cover shows a section of a lymph node lesion from a patient with malignant melanoma. Immunohistochemical staining demonstrates HLA class II expression on the majority of melanoma cells. For details, see the article by Stupia and colleagues on page 2894 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
Obituary
CCR Translations
CCR Perspectives in Regulatory Science and Policy
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
Andrea C. Baines; Maryam Sarraf Yazdy; Yvette L. Kasamon; Rachel Ershler; Emily Y. Jen; Bindu Kanapuru; Nicholas C. Richardson; Ashley Lane; Theresa Carioti; Marc R. Theoret; Richard Pazdur; Nicole J. Gormley
Review
Perspectives
Research Briefs: Clinical Trial Brief Reports
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer
Gary N. Schwartz; Peter A. Kaufman; Karthik V. Giridhar; Jonathan D. Marotti; Mary D. Chamberlin; Bradley A. Arrick; Grace Makari-Judson; Matthew P. Goetz; Shannon M. Soucy; Fred Kolling; Eugene Demidenko; Todd W. Miller
Clinical Trials: Targeted Therapy
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
David Levitz; Yogen Saunthararajah; Kateryna Fedorov; Lauren C. Shapiro; Ioannis Mantzaris; Aditi Shastri; Noah Kornblum; R. Alejandro Sica; Nishi Shah; Marina Konopleva; Kira Gritsman; Ira Braunschweig; Dennis L. Cooper; Kith Pradhan; Amit Verma; Eric J. Feldman; Mendel Goldfinger
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Sarat Chandarlapaty; Maura N. Dickler; Jose Alejandro Perez Fidalgo; Rafael Villanueva-Vázquez; Jennifer Giltnane; Mary Gates; Ching-Wei Chang; Sravanthi Cheeti; Jill Fredrickson; Xiaojing Wang; Ann Collier; Heather M. Moore; Ciara Metcalfe; Jennifer Lauchle; Eric W. Humke; Aditya Bardia
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang; Zhiyong Deng; Yong Ding; Wei Fu; Xianhe Xie; Linfa Li; Xiaohui He; Zhongwei Lv; Qingjie Ma; Zan Shen; Zhuming Guo; Zhendong Chen; Yali Cui; Jian Tan; Zairong Gao; Shanghua Jing; Keyi Lu; Xianyang Luo; Yuan Zhang; Yong Fang; Zhendong Li; Yizhuang Cheng; Shangtong Lei; Sha Luan; Guang Chen; Guihua Wang; Liqing Wu; Lingling Liu
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Stephanie L. Wethington; Payal D. Shah; Lainie Martin; Janos L. Tanyi; Nawar Latif; Mark Morgan; Drew A. Torigian; Diego Rodriguez; Simon A. Smith; Emma Dean; Susan M. Domchek; Ronny Drapkin; Ie-Ming Shih; Eric J. Brown; Wei-Ting Hwang; Deborah K. Armstrong; Stephanie Gaillard; Robert Giuntoli; Fiona Simpkins
Clinical Trials: Immunotherapy
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
Oliver Dorigo; Amit M. Oza; Tanja Pejovic; Prafull Ghatage; Sharad Ghamande; Diane Provencher; Lisa D. MacDonald; Heather Torrey; Valarmathy Kaliaperumal; Walead Ebrahimizadeh; Heather A. Hirsch; Yogesh Bramhecha; Jeannine Villella; Stephan Fiset
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
Chunhui Zhou; Yan Li; Jiaping Li; Botian Song; Hanfeng Li; Bin Liang; Shanzhi Gu; Haiping Li; Changyong Chen; Sai Li; Changli Peng; Fei Liu; Juxiong Xiao; Xueying Long; Ping Li; Zhengping Xiong; Xiaoping Yi; Weihua Liao; Liangrong Shi
Precision Medicine and Imaging
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Sofie H. Tolmeijer; Emmy Boerrigter; Takayuki Sumiyoshi; Edmond M. Kwan; Sarah W.S. Ng; Matti Annala; Gráinne Donnellan; Cameron Herberts; Guillemette E. Benoist; Paul Hamberg; Diederik M. Somford; Inge M. van Oort; Jack A. Schalken; Niven Mehra; Nielka P. van Erp; Alexander W. Wyatt
Translational Cancer Mechanisms and Therapy
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Luna De Sutter; Agnieszka Wozniak; Jasper Verreet; Ulla Vanleeuw; Lore De Cock; Nina Linde; Christine Drechsler; Christina Esdar; Raf Sciot; Patrick Schöffski
Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Amy C. Degnim; Brittany L. Siontis; Safia K. Ahmed; Tanya L. Hoskin; Tina J. Hieken; James W. Jakub; Christian L. Baum; Courtney Day; Sarah E. Schrup; Lauren Smith; Jodi M. Carter; Tiffany M. Sae Kho; Katrina N. Glazebrook; Aparna Vijayasekaran; Scott H. Okuno; Ivy A. Petersen
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Simone Stupia; Christina Heeke; Alicia Brüggemann; Anne Zaremba; Beatrice Thier; Julia Kretz; Antje Sucker; Manuel Philip; Gennadiy Zelinskyy; Soldano Ferrone; Alexander Roesch; Susanne Horn; Eva Hadaschik; Dirk Schadendorf; Mirko Trilling; Ulf Dittmer; Klaus Griewank; Fang Zhao; Annette Paschen
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Brooke Horowitch; Daniel Y. Lee; Min Ding; Sandra Martinez-Morilla; Thazin Nwe Aung; Feriel Ouerghi; Xueting Wang; Wei Wei; William Damsky; Mario Sznol; Harriet Kluger; David L. Rimm; Jeffrey J. Ishizuka
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
Christopher T. Letson; Maria E. Balasis; Hannah Newman; Moritz Binder; Alexis Vedder; Fumi Kinose; Markus Ball; Traci Kruer; Ariel Quintana; Terra L. Lasho; Christy M. Finke; Luciana L. Almada; Jennifer M. Grants; Guolin Zhang; Martin E. Fernandez-Zapico; Alexandre Gaspar-Maia; Jeffrey Lancet; Rami Komrokji; Eric Haura; David A. Sallman; Gary W. Reuther; Aly Karsan; Uwe Rix; Mrinal M. Patnaik; Eric Padron
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds